Micregen is a UK based biotech company, established in 2015 by leading stem cell scientists to translate their lifetimes work through to patient benefit. Their stem cell derived therapeutics, referred to as Secretomix, will have a significant impact on many conditions from neonatal therapies through to the many inflammatory and degenerative conditions associated with ageing. Our interest in this company stemmed from the huge clinical potential to reduce morbidity, mortality and increase quality of life. As with all our investments we were significantly influenced by the quality of the management team.

Visit website: Micregen